| RNA‐binding motif protein 39 (RBM39): an emerging cancer target Y Xu, A Nijhuis, HC Keun British journal of pharmacology 179 (12), 2795-2812, 2022 | 44 | 2022 |
| Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma A Nijhuis, A Sikka, O Yogev, L Herendi, C Balcells, Y Ma, E Poon, ... Nature Communications 13 (1), 1380, 2022 | 41 | 2022 |
| The transient receptor potential ankyrin type 1 plays a critical role in cortical spreading depression L Jiang, Y Wang, Y Xu, D Ma, M Wang Neuroscience 382, 23-34, 2018 | 33 | 2018 |
| DDR1 autophosphorylation is a result of aggregation into dense clusters DS Corcoran, V Juskaite, Y Xu, F Görlitz, Y Alexandrov, C Dunsby, ... Scientific reports 9 (1), 17104, 2019 | 27 | 2019 |
| Translocating a high-affinity designer TIMP-1 to the cell membrane for total renal carcinoma inhibition: Putting the prion protein to good use B Jiang, Y Xu, Y Zhang, MH Lee Molecular and Cellular Biology, 2019 | 6 | 2019 |
| Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma Y Xu, S Spear, Y Ma, MP Lorentzen, M Gruet, F McKinney, Y Xu, ... Cell Reports 42 (10), 2023 | 5 | 2023 |
Anke NijhuisImperial College, London在 imperial.ac.uk 的电子邮件经过验证
